Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

6507 Background: Management of adult ALL patients who relapse is challenging due to highly drug resistant disease and frequent residual therapy-induced toxicity. The increasing success of Salvage 1...